Elevated PAI-1 levels are associated with insulin resistance, endothelial dysfunction, liver fibrosis, and elevated cardiovascular risk, making this inhibitor a key systemic indicator of metabolic derangement [6]. Here, SERPINE1 is linked to Hepatic fibrosis.